Stay updated with breaking news from Processa Pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Processa Pharmaceuticals (NASDAQ:PCSA – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday, Zacks.com reports. According to Zacks, “Processa Pharmaceuticals, Inc. is focused on the development of drug products which intended to improve the survival and/or quality […]
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) saw a large drop in short interest in February. As of February 28th, there was short interest totalling 93,000 shares, a drop of 18.6% from the February 13th total of 114,300 shares. Based on an average trading volume of 36,300 shares, the short-interest ratio is presently 2.6 days. […]
HANOVER, MD., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical stage company...
Epilepsy Pipeline Analysis: 70+ Key Pipeline Therapies and 70+ Key Pharma Players are Looking Out in the Epilepsy Pipeline Landscape
Epilepsy Pipeline Analysis: 70+ Key Pipeline Therapies and 70+ Key Pharma Players are Looking Out in the Epilepsy Pipeline Landscape